Fig. 2: Repeat CHMI Clinical Trial CONSORT Diagram.

Twenty-seven participants were enrolled over the course of the study to either receive sequential controlled human malaria infections (CHMI) (14) or a single CHMI (13) as controls for mosquito infectivity. Of the 14 participants enrolled to received repetitive CHMIs 10 completed the mock CHMI, and an additional 4 were enrolled at CHMI 2 as replacements for the 4 original participants that withdrew. In total, 5 participants received 4 infectious CHMIs and 3 participants received 3 infectious CHMI and were included in the final analysis.